Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Asia 2022 | Standard of care of CAR-T therapies for B-cell malignancies

Won-Seog Kim • 24 Nov 2022
ESMO Asia 2022
Acute Lymphoblastic Leukemia B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma

Won-Seog Kim, MD, PhD, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, talks on the potential of CAR-T therapy for B-cell malignancies, including non-Hodgkin lymphoma and acute lymphoblastic leukemia (ALL). Key challenges include the high cost and complex manufacturing of CAR-T cells as well as reducing toxicities associated with CAR-T therapy. Dr Kim also discusses efforts to develop allogeneic CAR-T therapies. This interview took place at the European Society for Medical Oncology (ESMO) Asia congress 2022 in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Won-Seog Kim

1:11
DISTINKT trial analysis: efficacy and safety of IMC-001 for R/R ENKTL
Won-Seog Kim • 16 Jun 2023
1:35
REDIRECT results: AFM13 in patients with CD30+ R/R PTCL
Won-Seog Kim • 16 Jun 2023
1:07
Golidocitinib in R/R PTCL: analysis of the JACKPOT8 trial
Won-Seog Kim • 16 Jun 2023
1:09
Interim analysis of anbal-cel for R/R DLBCL
Won-Seog Kim • 16 Jun 2023

Related Videos

4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
5:14
Is transplantation and chemotherapy still necessary for all patients with Ph+ ALL?
Robin Foà • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals